Matthias Schwab MD

Dr. Matthew Schwab MD is Professor and Chair of Clinical Pharmacology at the University of Tuebingen and in addition director of the Department of Clinical Pharmacology, University Hospital, Tuebingen, Germany. Currently approx. 100 physicians, biologists, pharmacologists, statisticians (holding Ph.D. or MD degrees), PhD-/MD-/master-students, highly qualified technical staff, and study nurses are employed at IKP.

The mission of the joint endeavors of IKP and RBK in Stuttgart is to take clinical pharmacological research from bench to bedside. IKP holds an international reputation in basic and clinical pharmacogenomic (PGx) research to explain interindividual drug responses related to genetic, non-genetic, and epigenetic factors and to identify novel drug targets on the basis of disease susceptibility. The ultimate goal of IKP is to provide new strategies for optimizing drug therapy based on each patient's determinants of drug efficacy and toxicity.

The research topic of IKP is particularly dedicated to the metabolism and transport of drugs and drug effects (e.g. expression, regulation, and function of drug-metabolizing enzymes, transporter molecules, and regulators like nuclear receptors). In addition initiation and conduct of clinical trials (particularly principle investigator-initiated trials, IIT) are major interests at IKP to demonstrate the clinical relevance and clinical utility of PGx biomarkers. Finally, IKP covers clinical pharmacology services like the drug information and safety center for outpatient physicians in the state of Baden-Württemberg supported by the Kassenärztliche Vereinigung of Baden-Württemberg.